Chemistry:Lodoxamide
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
N,N′-(2-Chloro-5-cyano-1,3-phenylene)dioxamic acid | |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C11H6ClN3O6 | |
| Molar mass | 311.63 g·mol−1 |
| Pharmacology | |
| 1=ATC code }} | S01GX05 (WHO) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Lodoxamide is an antiallergic pharmaceutical drug. It is marketed under the tradename Alomide in the UK. Like cromoglicic acid it acts as a mast cell stabilizer.[1] In 2014 lodoxamide and bufrolin were found to be potent agonists at the G protein-coupled receptor 35, an orphan receptor believed to play a role in inflammatory processes, pain and the development of stomach cancer.[2]
See also
References
- ↑ Avunduk, A. M.; Avunduk, M. C.; Kapicioglu, Z.; Akyol, N.; Tavli, L. (2000). "Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis". Ophthalmology 107 (7): 1333–1337. doi:10.1016/S0161-6420(00)00089-0. PMID 10890862.
- ↑ MacKenzie, AE; Caltabiano, G; Kent, TC; Jenkins, L; McCallum, JE; Hudson, BD; Nicklin, SA; Fawcett, L et al. (2014). "The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35.". Molecular Pharmacology 85 (1): 91–104. doi:10.1124/mol.113.089482. ISSN 0026-895X. PMID 24113750.
 |  |
